Olathe, Kansas
United States
32
2026-01-08
The entities that hold a legal rights for patent applications filed by inventor Phadke Deepak:
Deepak Phadke from Olathe, US has applied for patents for these inventions. The list has both pending applications and granted patents:
Liquid Tasimelteon Formulations and Methods of Use Thereof
#2 | 2025-10-16HIGHLY PURIFIED PHARMACEUTICAL GRADE TASIMELTEON
#3 | 2025-03-20Liquid Tasimelteon Formulations and Methods of Use Thereof
#4 | 2024-10-10Highly purified pharmaceutical grade tasimelteon
#5 | 2024-10-03MELATONIN AGONIST TREATMENT
#6 | 2024-01-18ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS
#7 | 2023-11-30Highly purified pharmaceutical grade tasimelteon
#8 | 2023-11-23Liquid Tasimelteon Formulations and Methods of Use Thereof
#9 | 2023-05-18Highly purified pharmaceutical grade tasimelteon
#10 | 2023-01-26Ophthalmic Pharmaceutical Compositions
#11 | 2023-01-26MELATONIN AGONIST TREATMENT
#12 | 2022-03-10Highly purified pharmaceutical grade tasimelteon
#13 | 2021-07-15Liquid tasimelteon formulations and methods of use thereof
#14 | 2021-06-17Liquid tasimelteon formulations and methods of use thereof
#15 | 2021-01-21Highly purified pharmaceutical grade tasimelteon
#16 | 2021-01-21ILOPERIDONE METABOLITE FOR USE IN THE TREATMENT OF PSYCHIATRIC DISORDERS
#17 | 2020-12-24MELATONIN AGONIST TREATMENT
#18 | 2020-06-18Highly purified pharmaceutical grade tasimelteon
#19 | 2019-01-03Highly purified pharmaceutical grade tasimelteon
#20 | 2018-08-30MELATONIN AGONIST TREATMENT
#21 | 2018-04-12Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
#22 | 2017-07-06Highly purifid pharmaceutical grade tasimelteon
#23 | 2017-06-22Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
#24 | 2016-12-08MELATONIN AGONIST TREATMENT
#25 | 2016-03-03Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
#26 | 2015-05-28Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide
#27 | 2015-03-19MELATONIN AGONIST TREATMENT
#28 | 2015-02-12Iloperidone metabolite for use in the treatment of psychiatric disorders
#29 | 2012-05-31USE OF A MELATONIN AGONIST FOR THE TREATMENT OF SLEEP DISORDERS INCLUDING PRIMARY INSOMNIA
#30 | 2009-08-20TREATMENT FOR DEPRESSIVE DISORDERS
#31 | 2009-04-23MELATONIN AGONIST TREATMENT
#32 | 2009-01-08Stable dosage formulations of imidazolylalkyl-pyridines
1066936 ⎘